NASDAQ:STSASatsuma Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Satsuma Pharmaceuticals Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $25.63 +2.84 (+12.46 %) (As of 08/5/2020 04:00 PM ET) Add Compare Share Today's Range$21.69Now: $25.63▼$25.7750-Day Range$23.00MA: $27.62▼$34.6952-Week Range$8.61Now: $25.63▼$36.10Volume250,158 shsAverage Volume61,486 shsMarket Capitalization$445.68 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a novel therapeutic product for the acute treatment of migraine. Its product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in Phase III clinical trials and can be self-administered with a proprietary pre-filled single-use nasal delivery device. The company was founded in 2016 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSatsuma Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $33.50, Satsuma Pharmaceuticals has a potential upside of 48.7% from its current price of $22.53.Amount of Analyst CoverageSatsuma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesSatsuma Pharmaceuticals has received 203 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSatsuma Pharmaceuticals has received 216 “underperform” votes. (Add your “underperform” vote.)Community SentimentSatsuma Pharmaceuticals has received 51.55% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Satsuma Pharmaceuticals and other stocks. Vote “Outperform” if you believe STSA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STSA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSatsuma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSatsuma Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Satsuma Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $196,421.00 in company stock.Percentage Held by Insiders39.20% of the stock of Satsuma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.40% of the stock of Satsuma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Satsuma Pharmaceuticals are expected to grow in the coming year, from ($2.85) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Satsuma Pharmaceuticals is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Satsuma Pharmaceuticals is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSatsuma Pharmaceuticals has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.71 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryRegional Banks SectorMedical Current SymbolNASDAQ:STSA Previous Symbol CUSIP85931930 CIK891106 Webwww.satsumarx.com Phone650-410-3200Debt Debt-to-Equity Ratio0.02 Current Ratio15.05 Quick Ratio15.05Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.64 per share Price / Book3.86Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees11 Outstanding Shares17,389,000Market Cap$445.68 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable $25.63 +2.84 (+12.46 %) (As of 08/5/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive STSA News and Ratings via Email Sign-up to receive the latest news and ratings for STSA and its competitors with MarketBeat's FREE daily newsletter. Satsuma Pharmaceuticals (NASDAQ:STSA) Frequently Asked Questions How has Satsuma Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Satsuma Pharmaceuticals' stock was trading at $23.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, STSA shares have increased by 7.9% and is now trading at $25.63. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Satsuma Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Satsuma Pharmaceuticals. When is Satsuma Pharmaceuticals' next earnings date? Satsuma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Satsuma Pharmaceuticals. How were Satsuma Pharmaceuticals' earnings last quarter? Satsuma Pharmaceuticals (NASDAQ:STSA) issued its earnings results on Tuesday, May, 12th. The financial services provider reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.01. View Satsuma Pharmaceuticals' earnings history. What price target have analysts set for STSA? 4 equities research analysts have issued twelve-month price objectives for Satsuma Pharmaceuticals' stock. Their forecasts range from $32.00 to $35.00. On average, they anticipate Satsuma Pharmaceuticals' share price to reach $33.50 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price. View analysts' price targets for Satsuma Pharmaceuticals. Has Satsuma Pharmaceuticals been receiving favorable news coverage? Media coverage about STSA stock has been trending somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Satsuma Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave headlines about the financial services provider a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term. View the latest news about Satsuma Pharmaceuticals. Are investors shorting Satsuma Pharmaceuticals? Satsuma Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 183,300 shares, an increase of 18.0% from the June 30th total of 155,300 shares. Based on an average daily volume of 71,200 shares, the short-interest ratio is currently 2.6 days. Approximately 1.5% of the shares of the company are sold short. View Satsuma Pharmaceuticals' Current Options Chain. Who are some of Satsuma Pharmaceuticals' key competitors? Some companies that are related to Satsuma Pharmaceuticals include Truist Financial (TFC), PNC Financial Services Group (PNC), First Republic Bank (FRC), Fifth Third Bancorp (FITB), M&T Bank (MTB), KeyCorp (KEY), SVB Financial Group (SIVB), Regions Financial (RF), Huntington Bancshares (HBAN), Commerce Bancshares (CBSH), Signature Bank (SBNY), Zions Bancorporation NA (ZION), Prosperity Bancshares (PB), East West Bancorp (EWBC) and Cullen/Frost Bankers (CFR). View all competitors. What other stocks do shareholders of Satsuma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include AbbVie (ABBV), Applied Therapeutics (APLT), Canadian Natural Resources (CNQ), Crispr Therapeutics (CRSP), Enbridge (ENB), Enterprise Products Partners (EPD), Gilead Sciences (GILD), GlaxoSmithKline (GSK), ImmunoGen (IMGN) and Karuna Therapeutics (KRTX). Who are Satsuma Pharmaceuticals' key executives? Satsuma Pharmaceuticals' management team includes the following people: Mr. John A. Kollins, Pres, CEO & Director (Age 56)Dr. Detlef F. Albrecht, Chief Medical Officer (Age 58)Mr. Thomas P. O'Neil, Chief Financial Officer (Age 54)Mr. Mic Iwashima, VP & Head of Operations (Age 41)Mr. Robert Schultz, VP & Head of CMC (Age 55) When did Satsuma Pharmaceuticals IPO? (STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO. What is Satsuma Pharmaceuticals' stock symbol? Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA." Who are Satsuma Pharmaceuticals' major shareholders? Satsuma Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Quantitative Systematic Strategies LLC (0.07%), SG Americas Securities LLC (0.03%) and UBS Group AG (0.01%). Company insiders that own Satsuma Pharmaceuticals stock include Detlef Albrecht, Group Holdings (Sbs) Advis Tpg, Louis F Centofanti, Rajeev M Shah and Thomas P O'neil. View institutional ownership trends for Satsuma Pharmaceuticals. Which institutional investors are buying Satsuma Pharmaceuticals stock? STSA stock was purchased by a variety of institutional investors in the last quarter, including Quantitative Systematic Strategies LLC, SG Americas Securities LLC, and UBS Group AG. Company insiders that have bought Satsuma Pharmaceuticals stock in the last two years include Group Holdings (Sbs) Advis Tpg, Louis F Centofanti, and Rajeev M Shah. View insider buying and selling activity for Satsuma Pharmaceuticals. How do I buy shares of Satsuma Pharmaceuticals? Shares of STSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Satsuma Pharmaceuticals' stock price today? One share of STSA stock can currently be purchased for approximately $25.63. How big of a company is Satsuma Pharmaceuticals? Satsuma Pharmaceuticals has a market capitalization of $445.68 million. The financial services provider earns $-28,170,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Satsuma Pharmaceuticals employs 11 workers across the globe. What is Satsuma Pharmaceuticals' official website? The official website for Satsuma Pharmaceuticals is www.satsumarx.com. How can I contact Satsuma Pharmaceuticals? Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 94080. The financial services provider can be reached via phone at 650-410-3200. This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
